These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19591795)

  • 1. Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells.
    Huaman MC; Mullen GE; Long CA; Mahanty S
    Vaccine; 2009 Aug; 27(38):5239-46. PubMed ID: 19591795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate.
    Graves SF; Kouriba B; Diarra I; Daou M; Niangaly A; Coulibaly D; Keita Y; Laurens MB; Berry AA; Vekemans J; Ripley Ballou W; Lanar DE; Dutta S; Gray Heppner D; Soisson L; Diggs CL; Thera MA; Doumbo OK; Plowe CV; Sztein MB; Lyke KE
    Vaccine; 2016 May; 34(23):2546-55. PubMed ID: 27087149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes.
    Sedegah M; Hollingdale MR; Farooq F; Ganeshan H; Belmonte M; Kim Y; Peters B; Sette A; Huang J; McGrath S; Abot E; Limbach K; Shi M; Soisson L; Diggs C; Chuang I; Tamminga C; Epstein JE; Villasante E; Richie TL
    PLoS One; 2014; 9(9):e106241. PubMed ID: 25211344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.
    Sedegah M; Tamminga C; McGrath S; House B; Ganeshan H; Lejano J; Abot E; Banania GJ; Sayo R; Farooq F; Belmonte M; Manohar N; Richie NO; Wood C; Long CA; Regis D; Williams FT; Shi M; Chuang I; Spring M; Epstein JE; Mendoza-Silveiras J; Limbach K; Patterson NB; Bruder JT; Doolan DL; King CR; Soisson L; Diggs C; Carucci D; Dutta S; Hollingdale MR; Ockenhouse CF; Richie TL
    PLoS One; 2011; 6(10):e24586. PubMed ID: 22003383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
    Tamminga C; Sedegah M; Maiolatesi S; Fedders C; Reyes S; Reyes A; Vasquez C; Alcorta Y; Chuang I; Spring M; Kavanaugh M; Ganeshan H; Huang J; Belmonte M; Abot E; Belmonte A; Banania J; Farooq F; Murphy J; Komisar J; Richie NO; Bennett J; Limbach K; Patterson NB; Bruder JT; Shi M; Miller E; Dutta S; Diggs C; Soisson LA; Hollingdale MR; Epstein JE; Richie TL
    Hum Vaccin Immunother; 2013 Oct; 9(10):2165-77. PubMed ID: 23899517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
    Chuang I; Sedegah M; Cicatelli S; Spring M; Polhemus M; Tamminga C; Patterson N; Guerrero M; Bennett JW; McGrath S; Ganeshan H; Belmonte M; Farooq F; Abot E; Banania JG; Huang J; Newcomer R; Rein L; Litilit D; Richie NO; Wood C; Murphy J; Sauerwein R; Hermsen CC; McCoy AJ; Kamau E; Cummings J; Komisar J; Sutamihardja A; Shi M; Epstein JE; Maiolatesi S; Tosh D; Limbach K; Angov E; Bergmann-Leitner E; Bruder JT; Doolan DL; King CR; Carucci D; Dutta S; Soisson L; Diggs C; Hollingdale MR; Ockenhouse CF; Richie TL
    PLoS One; 2013; 8(2):e55571. PubMed ID: 23457473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
    Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
    Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV
    J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.
    Terheggen U; Drew DR; Hodder AN; Cross NJ; Mugyenyi CK; Barry AE; Anders RF; Dutta S; Osier FH; Elliott SR; Senn N; Stanisic DI; Marsh K; Siba PM; Mueller I; Richards JS; Beeson JG
    BMC Med; 2014 Oct; 12():183. PubMed ID: 25319190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
    Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ
    J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
    Kennedy MC; Wang J; Zhang Y; Miles AP; Chitsaz F; Saul A; Long CA; Miller LH; Stowers AW
    Infect Immun; 2002 Dec; 70(12):6948-60. PubMed ID: 12438374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.
    Pichyangkul S; Tongtawe P; Kum-Arb U; Yongvanitchit K; Gettayacamin M; Hollingdale MR; Limsalakpetch A; Stewart VA; Lanar DE; Dutta S; Angov E; Ware LA; Bergmann-Leitner ES; House B; Voss G; Dubois MC; Cohen JD; Fukuda MM; Heppner DG; Miller RS
    Vaccine; 2009 Dec; 28(2):452-62. PubMed ID: 19857448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
    Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
    Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein.
    Sedegah M; Kim Y; Peters B; McGrath S; Ganeshan H; Lejano J; Abot E; Banania G; Belmonte M; Sayo R; Farooq F; Doolan DL; Regis D; Tamminga C; Chuang I; Bruder JT; King CR; Ockenhouse CF; Faber B; Remarque E; Hollingdale MR; Richie TL; Sette A
    Malar J; 2010 Aug; 9():241. PubMed ID: 20735847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial.
    Lyke KE; Daou M; Diarra I; Kone A; Kouriba B; Thera MA; Dutta S; Lanar DE; Heppner DG; Doumbo OK; Plowe CV; Sztein MB
    Vaccine; 2009 Mar; 27(15):2171-6. PubMed ID: 19356621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
    Younis S; Faber BW; Kocken CHM; Remarque EJ
    BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.
    Pichyangkul S; Kum-Arb U; Yongvanitchit K; Limsalakpetch A; Gettayacamin M; Lanar DE; Ware LA; Stewart VA; Heppner DG; Mettens P; Cohen JD; Ballou WR; Fukuda MM
    Infect Immun; 2008 Jan; 76(1):229-38. PubMed ID: 17954725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.
    Barbosa A; Naniche D; Aponte JJ; Manaca MN; Mandomando I; Aide P; Sacarlal J; Renom M; Lafuente S; Ballou WR; Alonso PL
    Infect Immun; 2009 Oct; 77(10):4502-9. PubMed ID: 19651872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.
    Sun P; Schwenk R; White K; Stoute JA; Cohen J; Ballou WR; Voss G; Kester KE; Heppner DG; Krzych U
    J Immunol; 2003 Dec; 171(12):6961-7. PubMed ID: 14662904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.